Person who experienced the adverse event (patient)
| Event ID | CASE | I F COD | FOLL SEQ | IMAGE | EVENT DT | MFR DT | FDA DT | REPT COD | MFR NUM | MFR SNDR | AGE | AGE COD | GNDR COD | E SUB | WT | WT COD | REPT DT | OCCP COD | DEATH DT | TO MFR | CONFID | REPORTER COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5903216 | 6547518 | F | 5903216-8 | 20080115 | 20080926 | 20080930 | EXP | DE-BRISTOL-MYERS SQUIBB COMPANY-14068134 | BRISTOL-MYERS SQUIBB COMPANY | 55 | YR | F | Y | 71 | KG | 20080930 | OT | GERMANY |
Drug(s) used by person
| Event ID | DRUG SEQ | ROLE COD | DRUGNAME | VAL VBM | ROUTE | DOSE VBM | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5903216 | 1010519791 | PS | CETUXIMAB | 2 | INTRAVENOUS | MOST RECENT ADMINISTRATION ON 11JAN08. RECEIVED 432.7 MG ON 18JAN08 AND 25JAN08 | |||||
| 5903216 | 1010519792 | SS | OXALIPLATIN | 1 | INTRAVENOUS | MOST RECENT INFUSION ON 30AUG07 | |||||
| 5903216 | 1010519793 | SS | BEVACIZUMAB | 2 | INTRAVENOUS | MOST RECENT INFUSION ON 28DEC07 | |||||
| 5903216 | 1010519794 | SS | CAPECITABINE | 2 | ORAL | FORM = TAB. MOST RECENT ADMINISTRATION ON 11JAN08. RECEIVED 502.5 MG ON 18JAN08 TAKEN 2595MG |
Indications of drugs used
| Event ID | DRUG SEQ | INDI PT |
|---|---|---|
| 5903216 | 1010519791 | COLORECTAL CANCER |
| 5903216 | 1010519792 | COLORECTAL CANCER |
| 5903216 | 1010519793 | COLORECTAL CANCER |
| 5903216 | 1010519794 | COLORECTAL CANCER |
Outcome of event
| Event ID | OUTC COD |
|---|---|
| 5903216 | HO |
Reactions reported
| Event ID | PT |
|---|---|
| 5903216 | MUSCLE SPASMS |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|
| 5903216 | 1010519791 | 20080122 | |||
| 5903216 | 1010519792 | 20070122 | 20070830 | ||
| 5903216 | 1010519793 | 20070122 | |||
| 5903216 | 1010519794 | 20080122 |